[1-(2,2,2-Trifluoroethylcarbamoyl)cyclopropyl]carbamic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [1-(2,2,2-Trifluoroethylcarbamoyl)cyclopropyl]carbamic acid
• 英文别名: [1-(2,2,2-trifluoroethylcarbamoyl)cyclopropyl]carbamic acid
• 化学式: C₇H₉F₃N₂O₃
• 分子量: 226.15
• InChiKey: IRXOOCUKWCLOQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO
  申请人：DOW AGROSCIENCES LLC

  公开号：US20140171313A1

  公开（公告）日：2014-06-19

  This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.

  这份文件揭示了具有以下公式（“公式一”）的分子以及与其相关的过程。
• HDAC6 inhibitory heterocyclic compound
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US10435399B2

  公开（公告）日：2019-10-08

  The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有 HDAC 抑制作用、可用于治疗中枢神经系统疾病（包括神经退行性疾病等）的杂环化合物，以及一种包含该化合物的药物。 本发明涉及一种由式（I）代表的化合物： 其中各符号如说明书中所定义，或其盐类。
• HETEROCYCLIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20190135799A1

  公开（公告）日：2019-05-09

  The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
• US9212164B2
  申请人：——

  公开号：US9212164B2

  公开（公告）日：2015-12-15
• US9701620B2
  申请人：——

  公开号：US9701620B2

  公开（公告）日：2017-07-11